Speculative Bullish Options Positioning in Bristol-Myers Squibb (BMY) -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Bristol-Myers Squibb (BMY) Announces Presentations at IASLC
September 27, 2017 5:07 PM EDTBristol-Myers Squibb Company (NYSE: BMY) today announced the presentation of 28 abstracts for Opdivo (nivolumab), alone and in combination with Yervoy (ipilimumab), targeted therapy or chemotherapy, at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan, from October 15-18. Data from company-sponsored studies, clinical collaborations and... More
Bristol-Myers Squibb (BMY) Investor Meeting Feedback Comments From Jefferies
September 27, 2017 7:54 AM EDTJefferies maintains Buy on Bristol-Myers Squibb Co. (NYSE: BMY) price target of $72.00.
Analyst Jeff Holford says business development remains a top priority at the company noting the firm remains agnostic on deal size and listed three criteria when evaluating... More
